• English
  • French

The Hutchinson Santé G-VIR® glove reduces the risk of HIV virus transmission in accidental needlesticks by 99%, according to a study published in the journal
Surgery in February 20131

LIANCOURT, France, February 26, 2013 /PRNewswire/ — The AIDS and hepatitis C viruses expose healthcare personnel to the risk of viral transmission (see the section Accidental exposure to blood: the contamination risks for healthcare personnel) as a result of:

Thanks to a new patented technology developed by Hutchinson Santé, an innovative player in the fight against infection risks and in the comfort of healthcare personnel, the G-VIR® glove reduces the risk of contamination in cases of accidental exposure to blood, as shown in the study published in the February edition of Surgery (read the opinion of Prof. Charles Edmiston, surgeon and epidemiologist in
- Milwaukee, United States-, co-author of the article).

The G-VIR® is an active protection glove, designed and developed to improve protection for carers against the risks of viral contamination. The G-VIR® is made up of 3 layers. The middle layer includes a disinfecting liquid dispersed as micro-droplets (see: G-VIR®, innovative technology for protecting carers): in the case of an accidental puncture, the disinfecting liquid is released on the inside and the outside of the sharp to inactivate the viruses.

The study presented in Surgery – the abstract of which is attached – is the first to test the efficacy of the G-VIR® in reducing the transmission of the AIDS virus – the studies carried out up to now had assessed the G-VIR®’s performance on a number of model viruses, such as BVDV, FIV, and HSV12 but never on HIV.


The study assessed the passage of the HIV 1 virus transmitted by a hollowed needle filled with contaminated blood, by comparing the G-VIR® to a standard double-layer surgical glove.

The two types of gloves were punctured using an automated pneumatically controlled device.

The number of infectious viruses surviving after passing through the gloves was determined by observing and then comparing their cytopathogenic effects on a human lymphocytic C8166 T-cell tissue culture.

While after passing through a standard double-layer surgical glove, a few hundred to more than a thousand viable infectious viruses were counted, only a few viruses (5 to 11) were found after passing through the G-VIR®, or an average reduction of 99%.

These results highlight the benefit of this innovative glove in protecting healthcare staff against accidental virus contamination.

G-VIR®, innovative technology for the protection of carers

The G-VIR® is a “bio-active” surgical glove designed to improve the protection of carers against the risk of contamination with enveloped viruses (AIDS, hepatitis C, etc.).

G-VIR® gloves are composed of:

The G-VIR® mechanism of action allows the maximum amount of disinfecting liquid to be directed to the point where the glove was punctured. The design was inspired by an everyday observation:

When you peel an orange, the pores in its skin release a liquid under pressure that can be projected over several metres. The projection takes place when the elastic strain energy is converted into pressure on the liquid.

The properties of each layer of the glove have been adjusted (viscoelastic characteristics, fill rate, micro-droplet size, etc.) to reproduce as closely as possible the effect observed on the structure of the orange peel: using these properties, and under the pressure of the puncture, the glove releases the disinfectant liquid towards the inside and the outside of the instrument.

This unique and innovate mechanism was the basis for a scientific article in the May 2004 edition of the journal Nature Materials3 .

Furthermore, an evaluation under clinical conditions, carried out in 2006 among over 600 healthcare professionals from more than 85 hospitals, tested the glove’s performance in real clinical conditions by collecting responses to a questionnaire.

The results of this study showed that the G-VIR®, which is as thick as double gloving, meets the surgical practice requirements of dexterity, comfort and strength.

G-VIR®, technology that contributes to the strategy of risk reduction,
according to Prof. Charles Edmiston, surgeon and epidemiologist (Milwaukee, United States).

“Overall, in hospitals, the highest proportion (33%) of percutaneous injuries occur in the operating room (25%) or the examination rooms (8%). In most cases, the injuries are caused by suture needles.

Injuries from sharp or cutting instruments are frequent among surgical teams, and are particularly problematic for surgical trainees. A study has shown that 99% of all surgical trainees have reported at least one injury during their years of training, and that in 53% of cases, the injury took place when caring for a “high-risk” patient.

As demonstrated by the results of the study published in the February 2013 edition of Surgery, G-VIR® gloves inactivate 99% of blood-borne viruses following accidental needlesticks.

During a surgical procedure, a potentially contaminated instrument such as a suture needle that pierces a G-VIR® glove passes through the antimicrobial layer before puncturing the skin. In this way, the glove provides a significant level of protection for the user.
The technology behind this antimicrobial surgical glove (which reduces the exposure of medical teams to pathogenic viruses (HIV or HCV) by 99%) is a factor in the strategy for reducing these risks, especially when personnel are exposed to high-risk patient populations."

Prof. Charles Edmiston

Surgeon and epidemiologist (Milwaukee, United States), co-author of the article published in Surgery.

Accidental exposure to blood in France:
the contamination risks for healthcare personnel

The risk of viral contamination to which carers are exposed is far from negligible.

In 2009, the RAISIN network (Réseau d’Alerte, d’Investigation et de Surveillance des Infections Nosocomiales, the Nosocomial Infection Warning, Surveillance and Investigation Network), recorded 16,472 instances of accidental exposure to blood in the 728 French healthcare establishments that belong to the network. This figure represents about 50 healthcare professionals exposed every day in France, for these healthcare facilities alone. Bu it doesn’t include accidental exposure recorded in other establishments in France, or accidental exposures that were not declared.

Epidemiological studies assess the risk of contamination following a percutaneous accidental exposure to blood4 at:

The risk of viral transmission by needlestick is potentiated by the width of the needle and the depth of penetration. The experimental procedure used in the study published in Surgery shows this risk.

About Hutchinson Santé

Founded in 2004, Hutchinson Santé’s objective is the design and sale of innovative synthetic surgical gloves in the field of medical protection and the prevention of infections. The company’s first product, the G-VIR®, was the first surgical glove in the world designed to protect carers against the risks of viral contamination (AIDS, hepatitis C) in case of accidental exposure to blood (needlesticks, cuts, contact with broken skin). Today, the glove is used in more than 200 French healthcare establishments and is available in over 30 countries.

The first company to develop an antiviral glove to protect carers against the risks of contamination, Hutchinson Santé broadened its range with two new innovative gloves:
The G-BactTM, an innovative glove designed to increase the level of protection for patients against surgical site infections (SSIs), the leading cause of mortality during surgery3 . In its core, the G-BactTM surgical glove has an exclusive antimicrobial layer that reduces the bacterial load transferred following micro-perforation by more than 99.99% compared to a standard surgical glove*.
The G-DermTM is a synthetic surgical glove made from the innovative material styrene-butadiene copolymer. It is free of natural latex proteins, accelerators and vulcanising agents. The G-DermTM glove is indicated for the primary and secondary prevention of type I and type IV allergies. It offers exceptional comfort and a safe barrier (AQL= 0.25). **
Today, Hutchinson Santé employs about thirty people at its plant located in France, dedicated exclusively to manufacturing its range of 3 products and to research and development.

Press and Communication Department:
MHC Communication
Marie-Hélène Coste – Véronique Simon
38 avenue Jean Jaurès – 94110 Arcueil (France)
Tel: +33-1-49-12-03-40

1Charles E.Edmiston Jr: Evaluation of an antimicrobial surgical glove to inactivate live human immunodeficiency following simulated glove puncture, Surgery 2013; 153:225-33

2Bovine Virus Diarrhoea Virus, feline immunodeficiency virus, herpes simplex virus type 1

3P.Sonntag et al., Biocide squirting from an elastomeric film, 2004, 3, N°5, 311-315


Accidents d’exposition au VIH. Bases scientifiques et recommandations pour la prise en charge, [Accidental exposure to HIV. Scientific basis and recommended actions for control], 1999, Paris, Bash; The real incidence of percutaneous injuries in the operating room-a prospective study, Swiss Surgery, 1999. 5: p.27-32.

Management of occupational exposures to blood-borne viruses, NEJM, 1995. Vol 332, n°7: p.444-451.

HIV transmission during invasive radiologic procedures: estimate based on computer modeling, AJR, 1996. Vol 166: p.263-267.
Risques de contamination accidentelle par le virus de l’immuno-déficience humaine : mise au point et conduite à tenir, [The risks of accidental human immunodeficiency virus contamination: review and management] Progrès en Urologie, 1999. Vol 9: p. 330-341.

The surgeon and HIV seropositive and AIDS patients, Acta chir belg, 1994. Vol 94:p. 189-190;

A case control study of HIV seroconversions in Health Care workers after percutaneous exposures to HIV infected blood, Infect Contr Hosp Epidemiol, 1995: p.536.
Risk for occupational transmission of human immunodeficiency virus type 1 associated with clinical exposures, Annals of internal medicine, 1990. Vol 113: p.740-746.

Risk of HIV infection in health care workers, Cuur prob surg 1992: p. 235.

For more information on the test protocols or results, contact us at:
AQL (Accepted Quality Level)

Photo Gallery

Related Links

Hutchinson Healthcare

Related Documents